Literature DB >> 17465232

Fas-1377A/G and FasL-844 T/C gene polymorphisms and epithelial ovarian cancer.

Uzay Gormus1, Arzu Ergen, Hulya Yilmaz, Burak Dalan, Sinan Berkman, Turgay Isbir.   

Abstract

BACKGROUND: The Fas receptor is known to be widely expressed in various tissues and FasL is highly expressed on cells of the immune system and also on cells of immune-privileged areas such as the eyes and brain. Ovarian cells are known to exhibit marked FasL immunoreactivity throughout follicular development; there may also be a relationship between Fas and FasL polymorphisms and the immune privileges of the epithelial ovarian cells. PATIENTS AND METHODS: The study included 47 epithelial ovarian carcinoma patients and 41 healthy subjects. Polymerase chain reaction (PCR) and restriction endonucleases were used to determine the polymorphic Fas and FasL genes.
RESULTS: The FasL CC genotype was found to increase the risk of ovarian carcinoma and a protective effect of the GGCT genotype was observed.
CONCLUSION: Because of the expressional aspects of the FasL-844T --> C polymorphism, individuals carrying the FasL-844C allele would be expected to have higher FasL expression on tumour cells compared with those carrying the FasL-844T allele. People with such a genotype show a tendency to develop various tumours.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17465232

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently.

Authors:  Sateesh Reddy Nallapalle; Sarika Daripally; V T S Vidudala Prasad
Journal:  Tumour Biol       Date:  2014-12-04

2.  The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies.

Authors:  Zhizhong Zhang; Lixin Qiu; Meilin Wang; Na Tong; Jin Li; Zhengdong Zhang
Journal:  Eur J Hum Genet       Date:  2009-04-01       Impact factor: 4.246

3.  FasL -844T/C and Fas -1377G/A: mutations of pulmonary adenocarcinoma in South China and their clinical significances.

Authors:  Hongguang Zhao; Wenhu Chen; Peng Du; Aihua Sun; Chenyu Zhuang; Jiali Tong; Lifang Wang
Journal:  Tumour Biol       Date:  2015-01-18

4.  FASL rs763110 polymorphism contributes to cancer risk: an updated meta-analysis involving 43,295 subjects.

Authors:  Lei Xu; Xin Zhou; Feng Jiang; Man-Tang Qiu; Zhi Zhang; Rong Yin; Lin Xu
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

Review 5.  FAS-1377 G/A (rs2234767) polymorphism and cancer susceptibility: a meta-analysis of 17,858 cases and 24,311 controls.

Authors:  Zhou Zhong-Xing; Mi Yuan-Yuan; Ma Hai Zhen; Zou Jian-Gang; Zhang Li-Feng
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

Review 6.  Association of the polymorphisms in the Fas/FasL promoter regions with cancer susceptibility: a systematic review and meta-analysis of 52 studies.

Authors:  Yeqiong Xu; Bangshun He; Rui Li; Yuqin Pan; Tianyi Gao; Qiwen Deng; Huiling Sun; Guoqi Song; Shukui Wang
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

7.  Death receptor (DR4) haplotypes are associated with increased susceptibility of gallbladder carcinoma in north Indian population.

Authors:  Rajani Rai; Kiran L Sharma; Surbhi Sharma; Sanjeev Misra; Ashok Kumar; Balraj Mittal
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.